• AAPL 170.57
  • TSLA 170.42
  • AMZN 178.77
  • MSFT 408.67
  • INTC 31.835
  • EURUSD 1.0689
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. ARYD.NASDAQ

ARYA Sciences Acquisition IV Corp (ARYD NASDAQ) stock market data APIs

$11.3297 -0(-0%) as of April 25, 2024

ARYA Sciences Acquisition IV Corp Financial Data Overview

11.33
11.3297
-
11.33
11.329
10.41-11.39
85 389 K
3 799 K
0
-0.28
-0.002
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ARYD',
Type: 'Common Stock',
Name: 'ARYA Sciences Acquisition IV Corp',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
ISIN: 'KYG316591083',
CUSIP: NULL,
CIK: '1838821',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2021-02-26',
InternationalDomestic: NULL,
Sector: 'Financial Services',
Industry: 'Shell Companies',
HomeCategory: NULL,
IsDelisted: false,
}

ARYA Sciences Acquisition IV Corp Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA 0
  • Earnings Per Share -0.22
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get ARYA Sciences Acquisition IV Corp Earnings via APIs

  • Latest Release 2023-12-31
  • EPS/Forecast NaN

Get ARYA Sciences Acquisition IV Corp End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get ARYA Sciences Acquisition IV Corp latest news via APIs

ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Market Conditions

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors a...
  • ARYA SCIENCES ACQUISITION CORP IV
  • BUSINESS CONTRACTS
  • NASDAQ:ARYD

ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Market Conditions

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors ann...
  • ADAM STONE
  • ARYA
  • ARYA IV
  • ARYA SCIENCES ACQUISITION CORP IV
  • BUSINESS COMBINATION
  • BUSINESS COMBINATION AGREEMENT
  • FORWARD-LOOKING STATEMENTS
  • MICHAEL ALTMAN
Do you have any questions?
support@eodhistoricaldata.com